Logo image of NHICU

NEWHOLD INVESTMENT CORP III (NHICU) Stock Overview

NASDAQ:NHICU - KYG6486E1281

10.35 USD
+0.04 (+0.39%)
Last: 9/9/2025, 4:30:01 PM
Fundamental Rating

2

NHICU gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. The financial health of NHICU is average, but there are quite some concerns on its profitability. NHICU does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NHICU had positive earnings in the past year.
NHICU Yearly Net Income VS EBIT VS OCF VS FCFNHICU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Industry RankSector Rank
ROA 1.06%
ROE 1.1%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NHICU Yearly ROA, ROE, ROICNHICU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2024 0 50 100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NHICU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NHICU Yearly Profit, Operating, Gross MarginsNHICU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2024

More info and screens

6

2. Health

2.1 Basic Checks

NHICU Yearly Shares OutstandingNHICU Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2024 5M 10M 15M 20M
NHICU Yearly Total Debt VS Total AssetsNHICU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 23.57 indicates that NHICU is not in any danger for bankruptcy at the moment.
NHICU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.57
ROIC/WACCN/A
WACCN/A
NHICU Yearly LT Debt VS Equity VS FCFNHICU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2024 0 50M 100M 150M

2.3 Liquidity

NHICU has a Current Ratio of 9.48. This indicates that NHICU is financially healthy and has no problem in meeting its short term obligations.
NHICU has a Quick Ratio of 9.48. This indicates that NHICU is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 9.48
Quick Ratio 9.48
NHICU Yearly Current Assets VS Current LiabilitesNHICU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2024 500K 1M 1.5M 2M 2.5M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year150%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NHICU Yearly Revenue VS EstimatesNHICU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 200M 400M 600M 800M
NHICU Yearly EPS VS EstimatesNHICU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 129.38, NHICU can be considered very expensive at the moment.
The average S&P500 Price/Earnings ratio is at 27.07. NHICU is valued rather expensively when compared to this.
NHICU is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 129.38
Fwd PE N/A
NHICU Price Earnings VS Forward Price EarningsNHICU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NHICU Per share dataNHICU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NHICU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEWHOLD INVESTMENT CORP III

NASDAQ:NHICU (9/9/2025, 4:30:01 PM)

10.35

+0.04 (+0.39%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)08-14 2025-08-14
Earnings (Next)N/A N/A
Inst Owners81.78%
Inst Owner Change-56.5%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap285.76M
Analysts0
Price TargetN/A
Short Float %0.03%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 129.38
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.43
P/tB 1.43
EV/EBITDA N/A
EPS(TTM)0.08
EY0.77%
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS7.23
TBVpS7.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.06%
ROE 1.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.48
Quick Ratio 9.48
Altman-Z 23.57
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year150%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A